JP2018522858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522858A5 JP2018522858A5 JP2017566338A JP2017566338A JP2018522858A5 JP 2018522858 A5 JP2018522858 A5 JP 2018522858A5 JP 2017566338 A JP2017566338 A JP 2017566338A JP 2017566338 A JP2017566338 A JP 2017566338A JP 2018522858 A5 JP2018522858 A5 JP 2018522858A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- treating
- subject
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 1
- 102100008614 IDO1 Human genes 0.000 claims 1
- 101710031171 IDO1 Proteins 0.000 claims 1
- 102100008615 IDO2 Human genes 0.000 claims 1
- 101710031174 IDO2 Proteins 0.000 claims 1
- 102100014437 TDO2 Human genes 0.000 claims 1
- 101710006302 TDO2 Proteins 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulators Drugs 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Claims (4)
- 請求項1〜19のいずれか一項に記載の化合物、および薬学的に許容し得る担体または希釈剤を含む医薬組成物。
- 有効量の請求項1〜19のいずれか一項に記載の化合物またはその薬学的に許容し得る塩を含む、がんを有する対象を治療するための医薬組成物。
- 有効量の請求項1〜19のいずれか一項に記載の化合物またはその薬学的に許容し得る塩を含む、がんを有する対象を治療するための医薬組成物であって、該医薬組成物は、有効な第二の抗がん治療(例、化学療法剤、標的化治療剤、放射線または手術)と組み合わせて使用される、医薬組成物。
- 有効量の請求項1〜19のいずれか一項に記載の化合物またはその薬学的に許容し得る塩を含む、がんを有する対象を治療するための医薬組成物であって、該医薬組成物は、有効量の、チェックポイント阻害剤(例、抗PD−1抗体、抗CTLA4抗体または抗PD−L1抗体)またはトリプトファン酸化阻害剤(例、IDO1、IDO2またはTDO2阻害剤)などの免疫調節剤と組み合わせて使用される、医薬組成物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021097834A JP7241810B2 (ja) | 2015-06-25 | 2021-06-11 | Hpk1阻害剤およびそれを用いる方法 |
JP2023034474A JP2023071911A (ja) | 2015-06-25 | 2023-03-07 | Hpk1阻害剤およびそれを用いる方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562184348P | 2015-06-25 | 2015-06-25 | |
US62/184,348 | 2015-06-25 | ||
PCT/CA2016/050734 WO2016205942A1 (en) | 2015-06-25 | 2016-06-23 | Hpk1 inhibitors and methods of using same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021097834A Division JP7241810B2 (ja) | 2015-06-25 | 2021-06-11 | Hpk1阻害剤およびそれを用いる方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018522858A JP2018522858A (ja) | 2018-08-16 |
JP2018522858A5 true JP2018522858A5 (ja) | 2019-07-25 |
JP6898868B2 JP6898868B2 (ja) | 2021-07-07 |
Family
ID=57584335
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017566338A Active JP6898868B2 (ja) | 2015-06-25 | 2016-06-23 | Hpk1阻害剤およびそれを用いる方法 |
JP2021097834A Active JP7241810B2 (ja) | 2015-06-25 | 2021-06-11 | Hpk1阻害剤およびそれを用いる方法 |
JP2023034474A Pending JP2023071911A (ja) | 2015-06-25 | 2023-03-07 | Hpk1阻害剤およびそれを用いる方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021097834A Active JP7241810B2 (ja) | 2015-06-25 | 2021-06-11 | Hpk1阻害剤およびそれを用いる方法 |
JP2023034474A Pending JP2023071911A (ja) | 2015-06-25 | 2023-03-07 | Hpk1阻害剤およびそれを用いる方法 |
Country Status (27)
Country | Link |
---|---|
US (3) | US10501474B2 (ja) |
EP (1) | EP3322711B1 (ja) |
JP (3) | JP6898868B2 (ja) |
KR (2) | KR102614872B1 (ja) |
CN (2) | CN113214287B (ja) |
AU (1) | AU2016282289B2 (ja) |
BR (2) | BR122023006150B1 (ja) |
CA (1) | CA2989684A1 (ja) |
CY (1) | CY1124489T1 (ja) |
DK (1) | DK3322711T3 (ja) |
EA (1) | EA035421B1 (ja) |
ES (1) | ES2872555T3 (ja) |
HK (1) | HK1255833A1 (ja) |
HR (1) | HRP20210895T1 (ja) |
HU (1) | HUE054159T2 (ja) |
IL (2) | IL283353B (ja) |
LT (1) | LT3322711T (ja) |
MA (1) | MA42456B1 (ja) |
MD (1) | MD3322711T2 (ja) |
MX (2) | MX2018000048A (ja) |
PL (1) | PL3322711T3 (ja) |
PT (1) | PT3322711T (ja) |
RS (1) | RS61919B1 (ja) |
SG (1) | SG10202105964RA (ja) |
SI (1) | SI3322711T1 (ja) |
TW (1) | TWI733679B (ja) |
WO (1) | WO2016205942A1 (ja) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE054159T2 (hu) * | 2015-06-25 | 2021-08-30 | Univ Health Network | HPK1 gátlók és azok alkalmazási módja |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
JP7076432B2 (ja) | 2016-09-09 | 2022-05-27 | インサイト・コーポレイション | Hpk1調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法 |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
CN110402248B (zh) * | 2017-03-15 | 2023-01-06 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
BR112019019555A2 (pt) * | 2017-03-30 | 2020-04-22 | Hoffmann La Roche | composto de fórmula i, composição farmacêutica, método de inibição de hpk1, método para melhorar uma resposta imune, método para tratar um distúrbio e uso do composto |
KR20190136028A (ko) * | 2017-03-30 | 2019-12-09 | 에프. 호프만-라 로슈 아게 | Hpk1 억제제로서의 나프티리딘 |
WO2018228925A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
WO2018228920A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
CA3079060A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
US11427578B1 (en) | 2017-07-18 | 2022-08-30 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
CN109721620B (zh) * | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
WO2019090198A1 (en) * | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
PL3755703T3 (pl) | 2018-02-20 | 2022-11-07 | Incyte Corporation | Pochodne n-(fenylo)-2-(fenylo)pirymidyno-4-karboksyamidu i związki pokrewne jako inhibitory hpk1 do leczenia nowotworu |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
JP7386842B2 (ja) | 2018-07-24 | 2023-11-27 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ナフチリジン化合物およびその使用 |
JP7386841B2 (ja) * | 2018-07-24 | 2023-11-27 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
TW202024053A (zh) * | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
TW202023558A (zh) * | 2018-10-03 | 2020-07-01 | 美商建南德克公司 | 8-胺基異喹啉化合物及其用途 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
AU2019373221B2 (en) * | 2018-10-31 | 2022-05-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity |
BR112021008255A2 (pt) | 2018-10-31 | 2021-08-03 | Gilead Sciences, Inc. | compostos de 6-azabenzimidazol substituídos como inibidores de hpk1 |
EP3894406A1 (en) | 2018-12-11 | 2021-10-20 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
US11168093B2 (en) | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
KR20210108433A (ko) * | 2018-12-26 | 2021-09-02 | 얀센 파마슈티카 엔.브이. | 티에노피리디논 화합물 |
WO2020193512A1 (en) | 2019-03-26 | 2020-10-01 | Janssen Pharmaceutica Nv | Bicyclic hpk1 inhibitors |
WO2020193511A1 (en) | 2019-03-26 | 2020-10-01 | Janssen Pharmaceutica Nv | Hpk1 inhibitors |
WO2020235902A1 (ko) * | 2019-05-17 | 2020-11-26 | 주식회사 보로노이 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
CR20220097A (es) | 2019-08-06 | 2022-06-01 | Incyte Corp | Formas sólidas de un inhibidor de hpk1 |
WO2021050964A1 (en) | 2019-09-13 | 2021-03-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
CN112552293A (zh) * | 2019-09-25 | 2021-03-26 | 珠海宇繁生物科技有限责任公司 | 一种protac小分子化合物及其应用 |
CA3153501A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
BR112022011115A2 (pt) * | 2020-01-09 | 2022-08-23 | Sumitomo Chemical Co | Composto heterocíclico e composição de controle de artrópode nocivo, incluindo o mesmo |
CA3169451A1 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
US20230144869A1 (en) * | 2020-04-13 | 2023-05-11 | University Health Network | Methods for treating cytokine release syndrome |
CN115698009A (zh) | 2020-05-01 | 2023-02-03 | 吉利德科学公司 | 抑制cd73的2,4-二氧代嘧啶化合物 |
MX2022014168A (es) * | 2020-05-11 | 2023-02-22 | Univ Health Network | Sal y formas de cristal de 4-amino-5-(6-(4-metilpiperazin-1-il)-ih benzo[d]imidazol-2-il)tieno[2,3-b]piridin-6(7h)-ona. |
WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
KR20230079059A (ko) * | 2020-09-30 | 2023-06-05 | 베이진 엘티디 | Hpk1 저해제로서의 3-[(1h-피라졸-4-일)옥시]피라진-2-아민 화합물 및 이의 용도 |
EP4240361A1 (en) * | 2020-11-09 | 2023-09-13 | Merck Sharp & Dohme LLC | 7-azole substituted 2-aminoquinazoline inhibitors of hpk1 |
CN116472041A (zh) * | 2020-11-24 | 2023-07-21 | 正大天晴药业集团股份有限公司 | 氘修饰的噻吩并吡啶酮化合物 |
EP4288437A1 (en) | 2021-02-05 | 2023-12-13 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
JP2024509192A (ja) | 2021-03-05 | 2024-02-29 | ニンバス サターン, インコーポレイテッド | Hpk1アンタゴニスト及びその使用 |
CN116888127A (zh) * | 2021-03-10 | 2023-10-13 | 轩竹生物科技股份有限公司 | 三并环类hpk1抑制剂及其用途 |
WO2022199676A1 (zh) * | 2021-03-26 | 2022-09-29 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
WO2022226667A1 (en) * | 2021-04-30 | 2022-11-03 | Ontario Institute For Cancer Research (Oicr) | Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1) |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022253252A1 (en) * | 2021-06-03 | 2022-12-08 | Silexon Biotech Co., Ltd. | Heterocyclic compounds useful as hpk1 inhibitors |
CN115433161A (zh) * | 2021-06-04 | 2022-12-06 | 轶诺(浙江)药业有限公司 | 新型hpk1抑制剂及其制备方法和应用 |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
US20230060354A1 (en) | 2021-06-23 | 2023-03-02 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
WO2023001794A1 (en) | 2021-07-20 | 2023-01-26 | Astrazeneca Ab | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer |
WO2023015199A1 (en) * | 2021-08-03 | 2023-02-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
WO2023023942A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same |
WO2023057882A1 (en) * | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
AU2022364646A1 (en) * | 2021-10-15 | 2024-03-28 | Lomond Therapeutics, Inc. | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF |
US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
WO2023109902A1 (zh) * | 2021-12-17 | 2023-06-22 | 海思科医药集团股份有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202333712A (zh) * | 2021-12-22 | 2023-09-01 | 加拿大健康網路大學 | 於急性骨髓性白血病或淋巴瘤之治療 |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023138612A1 (en) * | 2022-01-19 | 2023-07-27 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as hpk1 inhibitors |
WO2023143384A1 (zh) * | 2022-01-27 | 2023-08-03 | 四川海思科制药有限公司 | 一种抑制或降解hpk1激酶的化合物及其在医药中的用途 |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
CN116462685A (zh) * | 2022-02-08 | 2023-07-21 | 和径医药科技(上海)有限公司 | 杂环化合物、包含其的药物组合物及其抗肿瘤应用 |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7314200A (en) * | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
EP1226119B1 (en) * | 1999-10-19 | 2005-03-16 | MERCK & CO. INC. | Tyrosine kinase inhibitors |
EP1313734B1 (en) * | 2000-09-01 | 2009-11-11 | Novartis Vaccines and Diagnostics, Inc. | Aza heterocyclic derivatives and their therapeutic use |
WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
US7119205B2 (en) | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
US8501750B2 (en) | 2007-05-21 | 2013-08-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
PT2262500T (pt) | 2008-04-11 | 2016-08-16 | Merck Patent Gmbh | Derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk) |
UA103617C2 (ru) | 2008-05-05 | 2013-11-11 | Мерк Патент Гмбх | Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк) |
JP5766820B2 (ja) | 2011-02-09 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pi3キナーゼ阻害剤としての複素環化合物 |
GB201114212D0 (en) * | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
HUE054159T2 (hu) | 2015-06-25 | 2021-08-30 | Univ Health Network | HPK1 gátlók és azok alkalmazási módja |
-
2016
- 2016-06-23 HU HUE16813437A patent/HUE054159T2/hu unknown
- 2016-06-23 JP JP2017566338A patent/JP6898868B2/ja active Active
- 2016-06-23 WO PCT/CA2016/050734 patent/WO2016205942A1/en active Application Filing
- 2016-06-23 DK DK16813437.7T patent/DK3322711T3/da active
- 2016-06-23 IL IL283353A patent/IL283353B/en unknown
- 2016-06-23 US US15/738,286 patent/US10501474B2/en active Active
- 2016-06-23 AU AU2016282289A patent/AU2016282289B2/en active Active
- 2016-06-23 CN CN202110534553.5A patent/CN113214287B/zh active Active
- 2016-06-23 SG SG10202105964RA patent/SG10202105964RA/en unknown
- 2016-06-23 MX MX2018000048A patent/MX2018000048A/es unknown
- 2016-06-23 MA MA42456A patent/MA42456B1/fr unknown
- 2016-06-23 CN CN201680048058.0A patent/CN107922431B/zh active Active
- 2016-06-23 EP EP16813437.7A patent/EP3322711B1/en active Active
- 2016-06-23 KR KR1020187001327A patent/KR102614872B1/ko active IP Right Grant
- 2016-06-23 EA EA201890059A patent/EA035421B1/ru not_active IP Right Cessation
- 2016-06-23 PL PL16813437T patent/PL3322711T3/pl unknown
- 2016-06-23 PT PT168134377T patent/PT3322711T/pt unknown
- 2016-06-23 CA CA2989684A patent/CA2989684A1/en active Pending
- 2016-06-23 KR KR1020237042987A patent/KR20240000617A/ko not_active Application Discontinuation
- 2016-06-23 RS RS20210675A patent/RS61919B1/sr unknown
- 2016-06-23 LT LTEP16813437.7T patent/LT3322711T/lt unknown
- 2016-06-23 SI SI201631189T patent/SI3322711T1/sl unknown
- 2016-06-23 MD MDE20180529T patent/MD3322711T2/ro unknown
- 2016-06-23 BR BR122023006150-0A patent/BR122023006150B1/pt active IP Right Grant
- 2016-06-23 BR BR112017027241-5A patent/BR112017027241B1/pt active IP Right Grant
- 2016-06-23 ES ES16813437T patent/ES2872555T3/es active Active
- 2016-06-24 TW TW105120043A patent/TWI733679B/zh active
-
2017
- 2017-12-11 IL IL256250A patent/IL256250B/en active IP Right Grant
-
2018
- 2018-01-08 MX MX2021011435A patent/MX2021011435A/es unknown
- 2018-11-21 HK HK18114909.1A patent/HK1255833A1/zh unknown
-
2019
- 2019-12-06 US US16/705,458 patent/US11059832B2/en active Active
-
2021
- 2021-06-07 HR HRP20210895TT patent/HRP20210895T1/hr unknown
- 2021-06-08 CY CY20211100498T patent/CY1124489T1/el unknown
- 2021-06-11 JP JP2021097834A patent/JP7241810B2/ja active Active
- 2021-07-12 US US17/372,717 patent/US20220002313A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034474A patent/JP2023071911A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018522858A5 (ja) | ||
CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
CY1122986T1 (el) | Παραγωγα 1,2,4-οξαδιαζολιου ως ανοσοτροποποιητες | |
CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
CY1124798T1 (el) | Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων | |
EA201790174A1 (ru) | Антипролиферативные соединения и способы их применения | |
CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
EA201591509A1 (ru) | Ингибиторы cdc7 | |
MX2017001976A (es) | Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano. | |
EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
WO2016133903A3 (en) | Combination therapy for cancer treatment | |
CL2015002346A1 (es) | Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
CY1121334T1 (el) | Αναστολεας κινασης aurora a | |
CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
SG11201608441YA (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
EA201691570A1 (ru) | Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
EA201990095A1 (ru) | КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb |